Arthur C. Theodore, MD

Associate Professor, Medicine

Arthur Theodore
72 E. Concord St Housman (R)

Biography

My expertise in presentation of scientific data, bedside education, communication and negotiation, conflict resolution, curriculum development, leading teams and meetings, solving problems, researching and presenting medical literature, quality improvement, strategic planning, delivering health care and comprehending law and ethics results from 14 years as Director of the Medical Intensive Care Unit, 31 years as an academic physician dedicated to education, research and clinical care, 6 years participation in the Ethics Committee and production of over 200 opinions and testimony in personal injury and medical malpractice.

Other Positions

  • Active Staff Privileges, Medicine, Boston Medical Center

Education

  • Boston University, MD
  • Beloit College, BS

Classes Taught

Publications

  • Published on 12/22/2016

    Tashkin DP, Volkmann ER, Tseng CH, Roth MD, Khanna D, Furst DE, Clements PJ, Theodore A, Kafaja S, Kim GH, Goldin J, Ariolla E, Elashoff RM. Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study II. Chest. 2017 Apr; 151(4):813-820. PMID: 28012804.

    Read at: PubMed
  • Published on 7/25/2016

    Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016 Sep; 4(9):708-719. PMID: 27469583.

    Read at: PubMed
  • Published on 7/15/2015

    Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, Johkoh T, Martinez FJ, Myers J, Protzko SL, Richeldi L, Rind D, Selman M, Theodore A, Wells AU, Hoogsteden H, Schünemann HJ. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015 Jul 15; 192(2):e3-19. PMID: 26177183.

    Read at: PubMed
  • Published on 9/1/2012

    Theodore AC, Tseng CH, Li N, Elashoff RM, Tashkin DP. Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study. Chest. 2012 Sep; 142(3):614-21. PMID: 22156609.

    Read at: PubMed
  • Published on 1/1/2010

    Theodore AC, Wilson KC. An unseen danger: frequency of posterior vessel wall penetration by needles during attempts to place internal jugular vein central catheters using ultrasound guidance. Crit Care Med. 2010 Jan; 38(1):345-6; author reply 346-7. PMID: 20023505.

    Read at: PubMed
  • Published on 4/1/2009

    Au K, Khanna D, Clements PJ, Furst DE, Tashkin DP. Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials. Curr Rheumatol Rep. 2009 Apr; 11(2):111-9. PMID: 19296883.

    Read at: PubMed
  • Published on 2/1/2008

    Marshall J, Finn CA, Theodore AC. Impact of a clinical pharmacist-enforced intensive care unit sedation protocol on duration of mechanical ventilation and hospital stay. Crit Care Med. 2008 Feb; 36(2):427-33. PMID: 18091554.

    Read at: PubMed
  • Published on 9/27/2007

    Strange C, Bolster MB, Roth MD, Silver RM, Theodore A, Goldin J, Clements P, Chung J, Elashoff RM, Suh R, Smith EA, Furst DE, Tashkin DP. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med. 2008 Jan 1; 177(1):91-8. PMID: 17901414.

    Read at: PubMed
  • Published on 8/23/2007

    Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, Goldin J, Arriola E, Strange C, Bolster MB, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel D, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Khanna D, Li N, Li G. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007 Nov 15; 176(10):1026-34. PMID: 17717203.

    Read at: PubMed
  • Published on 5/1/2007

    Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Clements PJ. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum. 2007 May; 56(5):1676-84. PMID: 17469162.

    Read at: PubMed

View 28 more publications: View full profile at BUMC

View all profiles